A total of 8 analyst ratings have been received for Elevance Health, with the consensus rating being Outperform. The average ...

Elevance Health (NYSE:ELV) on Thursday issued its preliminary financial results for Q1 2025, projecting $9.61 of GAAP net ...

FDA-cleared CureSight™ therapy now reimbursed by Elevance Health, expanding access to effective digital treatment for lazy ...

For full-year 2024, Elevance reported $175.2 billion in revenue, an increase of 2.9% over its $170.2 billion haul in 2023.

Elevance (ELV) stock thrives with fee-based plans, preventive care, and disciplined capital management, ensuring growth and strong investor returns. See more.

Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.

Elevance continues to expect its Medicare Advantage program to hit 2.2 million to 2.25 million members in 2025, and for adjusted earnings to be $34.15 to $34.85 a share.

Elevance Health will beat its earnings guidance for the first quarter despite high Medicare Advantage costs, the company announced Thursday. The health insurer reported that while Medicare ...

In a regulatory filing, Elevance Health (ELV) noted it will release its first quarter 2025 financial results on April 22. “First quarter ...

In a regulatory filing, Elevance Health (ELV) noted it will release its first quarter 2025 financial results on April 22. The company expects ...

Baird notes Elevance Health (ELV) pre-announced a Q1 earnings beat with adjusted EPS of $11.97 vs. $11.62 implied guide, vs. $11.32 street, vs. its $11.63. The company cites medical costs ...